Sugi Predict

Sugi Predict / Compounds / SCHEMBL5370281

SCHEMBL5370281

SCHEMBL5370281

O=S(=O)(OC1=CCCc2ccc(Cl)cc21)C(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 5/20 0.37
▸ DRD3 P35462 2/20 0.37
▸ CHRM1 P11229 1/20 0.37
▸ DRD4 P21917 1/20 0.37
▸ F7 P08709 1/20 0.36
▸ PARP1 P09874 1/20 0.36
▸ F3 P13726 1/20 0.36
▸ PARP10 Q53GL7 1/20 0.36
▸ CNR2 P34972 1/20 0.35
▸ METAP1 P53582 1/20 0.34
▸ HTR1D P28221 1/20 0.33
▸ PDE4A P27815 1/20 0.32
▸ PDE4C Q08493 1/20 0.32
▸ PDE4D Q08499 1/20 0.32
▸ ESR1 P03372 1/20 0.32
▸ ESR2 Q92731 1/20 0.32
▸ S100A4 P26447 1/20 0.31
▸ ADORA2A P29274 1/20 0.31
▸ ADORA1 P30542 1/20 0.31
▸ BACE1 P56817 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5379087 0.85 KDM4C (0.39) DRD2DRD3CHRM1DRD4PARP1
SCHEMBL19616624 0.84 METAP1 (0.37) DRD2DRD3CHRM1DRD4PARP1
SCHEMBL22685317 0.84 TDP1 (0.39) DRD2DRD3PARP1PARP10METAP1
SCHEMBL13392254 0.84 ESR2 (0.42) DRD2DRD3HTR1DESR1ESR2
SCHEMBL29756733 0.82 MPO (0.44) DRD2DRD3CHRM1DRD4METAP1
SCHEMBL5847372 0.82 MPO (0.44) DRD2DRD3CHRM1DRD4METAP1
SCHEMBL30475404 0.80 DRD2 (0.40) DRD2DRD3CHRM1DRD4HTR1D
SCHEMBL5104747 0.80 DRD2 (0.40) DRD2DRD3CHRM1DRD4HTR1D
SCHEMBL22360909 0.80 DRD2 (0.42) DRD2DRD3CHRM1DRD4HTR1D
SCHEMBL5364953 0.79 DRD2 (0.31) DRD2DRD3HTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
EP-3710439-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-02-15 — — EP disclosed
EP-3710439-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-02-15 — — EP disclosed
US-11267812-B2 KRAS G12C inhibitors Mirati Therapeutics, Inc. (US) 2022-03-08 — — US disclosed
EP-3458445-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2021-02-17 — — EP disclosed
CN-111989321-A KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2020-11-24 — — CN disclosed
EP-3710439-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2020-09-23 — — EP disclosed
US-20200262837-A1 KRAS G12C INHIBITORS ARRAY BIOPHARMA INC. 2020-08-20 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 — — WO disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 — — WO disclosed
US-7160888-B2 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia WARNER LAMBERT COMPANY LLC (US) 2007-01-09 — — US disclosed
US-20060287309-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC 2006-12-21 — — US disclosed
US-20060287310-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC 2006-12-21 — — US disclosed
EP-1660497-A1 [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA Warner-Lambert Company LLC (US) 2006-05-31 — — EP disclosed
WO-2005019215-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC (US) 2005-03-03 — — WO disclosed
US-20050043309-A1 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia WARNER-LAMBERT COMPANY LLC 2005-02-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043309-A1 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia DRD1, DRD2, DRD3 DRD2 2/4885DRD3 3/4885CHRM1 35/4885
US-20200262837-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS DRD2 4727/4885DRD3 4776/4885CHRM1 4874/4885
US-11267812-B2 KRAS G12C inhibitors KRAS, NRAS, HRAS DRD2 4727/4885DRD3 4776/4885CHRM1 4874/4885
US-20240101553-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS DRD2 4727/4885DRD3 4776/4885CHRM1 4874/4885
US-20060287309-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA DRD1, DRD2, DRD3 DRD2 2/4885DRD3 3/4885CHRM1 35/4885
US-20060287310-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA DRD1, DRD2, DRD3 DRD2 2/4885DRD3 3/4885CHRM1 35/4885
US-20180072723-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS DRD2 4727/4885DRD3 4776/4885CHRM1 4874/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS DRD2 4727/4885DRD3 4776/4885CHRM1 4874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.